Credo VitaPCR™ SARS-CoV-2 RNA detection Assay can correctly detect the new Omicron strain B.1.1.529 BA.1 and its sublineage BA.2 (stealth version)

In response to the new Omicron variant (also known as B.1.1.529), we, Credo Diagnostics Biomedical Pte Ltd, have performed the BLASTn analysis (with the oligonucleotide primers and probes of the assays involving SARS-CoV-2 detection) against the sequences listed in GISAID on December 17th, 2021.

According to our analysis, we confirm that our SARS-CoV-2 RNA detection assay is capable of correctly detecting the new Omicron strain, including B.1.1.529 BA.1 and BA.2.

Meanwhile. we continue to affirm that our SARS-CoV-2 RNA detection assay is still capable of detecting the following earlier variant strains correctly

Another four Variants of Concern (VOC):
． Alpha variant: known as B.1.1.7
． Beta variant: known as B.1.351
． Gamma variant: known as P.1
． Delta variant: known as B.1.617.2

Two Variants of Interest (VOI):
． Lambda variant: known as C.37
． Mu variant: known as B.1.621

The other six variants:
． Eta variant: known as B.1.525
． Iota variant: known as B.1.526
． Kappa variant: known as B.1.617.1
． Zeta variant: known as P.2
． Epsilon variant: known as B.1.427/B.1.429
． Indian variant: known as B.1.617.3